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Harnessing Nature’s Diversity: 
Discovering organophosphate 
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low molecular weight proteins
Reed B. Jacob1, Kenan C. Michaels2, Cathy J. Anderson2, James M. Fay1 & Nikolay V. Dokholyan1
Organophosphate poisoning can occur from exposure to agricultural pesticides or chemical 
weapons. This exposure inhibits acetylcholinesterase resulting in increased acetylcholine levels 
within the synaptic cleft causing loss of muscle control, seizures, and death. Mitigating the effects 
of organophosphates in our bodies is critical and yet an unsolved challenge. Here, we present a 
computational strategy that integrates structure mining and modeling approaches, using which 
we identify novel candidates capable of interacting with a serine hydrolase probe (with equilibrium 
binding constants ranging from 4 to 120 μM). One candidate Smu. 1393c catalyzes the hydrolysis 
of the organophosphate omethoate (kcat/Km of (2.0 ± 1.3) × 10−1 M−1s−1) and paraoxon (kcat/Km of 
(4.6 ± 0.8) × 103 M−1s−1), V- and G-agent analogs respectively. In addition, Smu. 1393c protects 
acetylcholinesterase activity from being inhibited by two organophosphate simulants. We demonstrate 
that the utilized approach is an efficient and highly-extendable framework for the development of 
prophylactic therapeutics against organophosphate poisoning and other important targets. Our 
findings further suggest currently unknown molecular evolutionary rules governing natural diversity of 
the protein universe, which make it capable of recognizing previously unseen ligands.
Effective organophosphate (OP) neutralization is a current problem facing both farmers, from agricultural poi-
soning, and armed forces and first responders, from chemical weapon threats1–5. Ease of dispersal, persistence of 
agents, and multiple intoxication paths transform agricultural OP pesticides into lethal and effective weapons6. 
Two main OP classes have been developed and weaponized, the phosphotriester G-agents, such as sarin, and the 
phosphonothioate ester V-agents, such as VX6,7. OPs inhibit acetylcholinesterase (AChE) by binding with high 
affinity to its active site. After AChE is inhibited, acetylcholine accumulates in the synaptic cleft causing brad-
ycardia, muscle seizures, and death through asphyxiation8. OP AChE inhibition proceeds through OP hydrol-
ysis, which causes the phosphorylation of the active site serine (Ser203) followed by de-alkylation at the rate 
of ~1.1 × 105 min−1 9. Due to political instabilities around the world, the chemical weapons threat has become 
substantial and requires the urgent development of counter-measures.
Current treatments are post-exposure and only moderately effective. One strategy of preventative measures 
are stoichiometric bioscavengers, proteins that compete with AChE for binding of organophosphates, thereby 
sequestering the organophosphates prior to AChE inhibition such as butyrylcholinesterase (BChE)10–12. However, 
BChE’s high production costs and large molecular weight limit the effective use of this bioscavenger10. A pro-
ducible, low molecular weight alternative is desirable. Two possible methods in which to obtain bioscavenger 
candidates are, a search of known proteins looking for promiscuous activity, or using de novo design to engineer 
proteins capable of binding OPs. Recent studies by Steinkellner et al. have identified two proteins with previ-
ously unknown promiscuous ene-reductase activity through geometric comparison13. Whereas, Rajagopalan 
et al. grafts a desired amino acid structure by de novo design protocols to create novel serine esterases14.
Here, we propose to search for low molecular weight bioscavenger candidates from within the set of proteins 
with known 3D structures and test plausible binding of organophosphates with molecular docking (Fig. 1a). 
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First, we apply a rigid substructure search algorithm Erebus15 to detect candidates from the protein databank 
mimicking the active site of AChE. Second, to predict the binding of organophosphates to the identified scaffold, 
we employ a molecular docking algorithm MedusaDock16 in which we account for both ligand and receptor flexi-
bility. We choose VX as a molecular probe for the in silico studies due to its exceptional lethality.
Our top three results are phosphoribosyl isomerase from Mycobacterium tuberculosis (PDB ID 2Y85), antigen 
85-A from Mycobacterium tuberculosis (PDB ID 1SFR), and Smu. 1393c from Streptococcus mutans (PDB ID 
4L9A). We validate the presence of the predicted binding interactions by testing with serine hydrolase probes. The 
results from a fluorescence polarization study indicate that all three candidates present OP binding interactions 
(with equilibrium binding constants ranging from 4 to 120 μ M). Of these candidates, we show that Smu. 1393c 
binds the probes through covalent modification of a serine mimicking AChE inhibition. We further demonstrate 
that Smu. 1393c can catalyze the hydrolysis of omethoate (kcat/Km of (2.0 ± 1.3) × 10−1 M−1s−1) and paraoxon 
(kcat/Km of (4.6 ± 0.8) × 103 M−1s−1), V- and G-agent analogs respectively. Additionally, Smu. 1393c protects 
AChE activity when exposed to two OP simulants and represents an OP bioscavenger candidate successfully 
identified using our computational workflow to mine structural databases for a novel target for a specific small 
molecule.
Results
Identification of putative candidate scaffolds. We first identify proteins with similar binding sites to 
AChE and BChE, using rigid substructure search algorithm, Erebus15 (Fig. 1a). Erebus algorithm rapidly extracts 
selected geometric features, such as inter-atomic pairwise distances, of a submitted query scaffold and then 
searches the PDB structures for matching features. The returned matches represent structures with a root mean 
square deviation (RMSD) where the query atoms and the matching result atoms fall within the desired cutoff 
parameter; in our case we choose a cutoff of less than five angstroms. Our query scaffold is composed of atoms 
selected from the active site of AChE (Fig. 1b). The number of returned results from this query is substantial 
(greater than 1,000) and require additional refinement, in which we apply the following three criteria: (i) molec-
ular weight below 40 kDa to ensure a low molecular weight; (ii) monomeric form of the retrieved solutions as 
detailed in the PDB file; and (iii) solvent accessibility of amino acids in the retrieved hits, which is a direct assess-
ment of whether the scaffold can be accessed by the OPs. We derive these criteria to overcome the limitations of 
BChE as a stoichiometric bioscavenger, namely the tetrameric structure and large molecular weight. After this 
refinement there are 21 protein candidates remaining (Supplementary Table 1).
Identification of top-ranked candidates. The classic binding mode of OPs involves covalent binding 
of the phosphate group to an activated serine. Prior to forming covalent interactions, non-covalent interactions 
assist in orienting the OP for a successful serine nucleophilic attack. We screen the 21 protein candidates using 
Figure 1. Two-stage search workflow with identified search parameters. (a) In this illustration we depict 
the computational protocol as a funnel where the various levels represent the initial population of PDB 
structures (top of funnel), the substructure search algorithm, Erebus, the docking algorithm, MedusaDock, 
and the final predicted candidates (below funnel). Alongside the illustration are two columns where we list 
the filter conditions at each step (first column) and the number of resulting structures for that step (second 
column). The search database comprises a snapshot of the PDB database from December 2014. (b) We show 
the geometric feature submitted to Erebus, which is comprised of four selected atoms from AChE (PDB ID 
1F8U) and the connections between them to represent the geometric feature that Erebus searches for. (c) We 
show the validation of MedusaDock where the docked VX molecule lies within the electron density map of the 
phosphorylated serine of BChE (PDB ID 2XQF).
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a flexible docking algorithm MedusaDock16,17 to model non-covalent protein-ligand interactions with VX as our 
ligand of interest (Fig. 1a and 1c). MedusaDock comprises a docking step intertwined with a scoring step, where 
the docking step creates a ligand rotamer library and searches the best fit within the flexible side chain rotamer 
library, using the MedusaScore force field16,17. We select the final candidates through ranking the 21 candidates by 
best-predicted binding energy (Supplementary Table 1). We find this method of ranking reveals a natural division 
between the candidates specifically: (i) an Erebus RMSD less than 4 Å; (ii) an average ligand RMSD less than 8 Å; 
and (iii) a MedusaDock predicted binding energy less than − 28 kcal/mol. The top resulting candidates are antigen 
85-A (PDB ID 1SFR) and phosphoribosyl isomerase (PDB ID 2Y85) from Myobacterium tuberculosis and Smu. 
1393c from Streptococcus mutans (PDB ID 4L9A).
To evaluate predicted binding modes of identified candidates, we compare predicted binding energy distri-
butions of organophosphate complexes with identified candidates to that of AChE and BChE. The greater the 
overlap between these distributions means the greater the probability of mimicking AChE OP interactions (Fig. 2 
and Supplementary Fig. 1). From docking simulations of all three candidates we find that the distance between 
the VX phosphate and predicted serine are less than 4 Å. This distance places the VX phosphate in a position for a 
serine nucleophilic attack. Additionally, the lowest predicted binding energy for each of our candidates’ is within a 
6 kcal/mol difference to the value of − 35.3 kcal/mol calculated for AChE (Supplementary Table 1). This difference 
indicates that our three candidates show predicted characteristics similar to AChE.
OP binding to top candidates. We validate predicted candidate similarity to AChE by using serine 
hydrolase probes, specifically ActiveX Tamra fluorophosphonate serine hydrolase probe (TFP-probe) and 
ActiveX Desthiobiotin fluorophosphonate serine hydrolase probe (DFP-probe) (Supplementary Fig. 2). These 
probes covalently phosphorylate, thereby labeling an active serine through a similar mechanism as organophos-
phates (Supplementary Fig. 3). The labeled serine is detectable via fluorescent gel (TFP-probe) or western blot 
(DFP-probe). A clearly defined band was present for Smu. 1393c, indicating positive phosphorylation (Fig. 3a and 
Supplementary Fig. 4). We did not detect a band for phosphoribosyl isomerase or antigen 85-A, suggesting no 
covalent binding though non-covalent interactions may still be present.
To quantify OP binding and check for non-covalent interactions, we use fluorescent polarization experiments 
utilizing the TFP-probe as substrate (Fig. 3b and Supplementarty Fig. 5). We find that Smu. 1393c has low micro-
molar binding (Kd = 4.17 ± 0.08 μ M). Though candidates’ antigen 85-A and phosphoribosyl isomerase show no 
covalent binding, there are non-covalent binding interactions with Kd’s of 20.9 ± 1.6 μ M and 120 ± 10 μ M, respec-
tively. All three candidates display binding interactions that validate the predictions from our computational 
workflow.
OP covalent binding to Smu. 1393c active site. To confirm that the location of the phosphorylation is 
as predicted from our computational workflow, we substitute serine (Ser99) to alanine in the Smu. 1393c’s pre-
dicted active site and perform labeling with both TFP-probe and DFP-probe and fluorescent polarization experi-
ments with TFP-probe. A visible band indicating phosphorylation was not present in the Ser99 mutation, thereby 
covalent binding was indeed eliminated from both the fluorescent gel and the western blot analysis (Fig. 3a). In 
Figure 2. Predicted Binding Energy distributions, structural overlays, and active site comparisons of 
candidate Smu. 1393c. (left) We show that Smu. 1393c (PDB ID 4L9A) (blue curve) is predicted to have 
binding interactions similar to control AChE (PDB ID 1F8U) and BChE (PDB ID 2XQF) (black and red 
curves respectively), through the overlap of predicted binding energy distributions of the organophosphate 
VX. (middle) We show Smu. 1393c’s lower molecular weight by structurally aligning Smu. 1393c (blue) with a 
molecular weight of ~33 kDa to a monomer of BChE (red) with a molecular weight of ~84 kDa. (right-top) We 
show that the predicted residues of Smu. 1393c (blue) align with the active site of BChE (red) in the absence of 
VX. (right-bottom) We show that the lowest energy pose of VX docked with Smu. 1393c (blue) and BChE (gray) 
place the phosphate in the correct orientation to irreversibly bind the active serine.
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addition, the removal of Ser99 drastically increases the Kd to greater than 300 μ M (Fig. 3b), suggesting that Ser99 
plays an essential role in OP binding.
Smu. 1393c catalytic activity. The literature indicates that Smu. 1393c has catalytic activity against 
p-nitrophenyl acetate (PNP-ac)18. We determine the activity rate of Smu. 1393c aided hydrolysis of PNP-ac to be 
kcat/Km of 6.3 ± 1.3 M−1s−1 (Fig. 3c, Table 1). Exposure to V-agent analog demeton-S-methyl (DSM) inhibits the 
PNP-ac hydrolysis activity with a Ki of 10.64 ± 1.9 μ M. Using a double reciprocal plot we find that DSM inhibits 
Smu. 1393c in a non-competitive manner (Supplementary Fig. 6), suggesting a potential second site that when 
bound has direct ramifications on activity.
Smu. 1393c protection of AChE. The inhibition of Smu. 1393c by organophosphate DSM indicates a pro-
tein/ligand interaction. We explore the ability of Smu. 1393c to protect AChE from inhibition through a quantita-
tive set of activity assays, modified from Cherny et al., designed to gauge the amount of AChE activity maintained 
after exposure to two OP simulates19. Specifically, we use demeton-S-methyl (DSM) as a V-agent analog and diiso-
propylfluorophosphate (DFP) as a G-agent analog (Fig. 3f, Supplementary Fig. 2, and Supplementary Table 2). 
Figure 3. Experimental results of candidate OP binding using serine hydrolase probes, AChE protection 
assays, and catalytic activity. (a) We show that candidate Smu. 1393c (PDB ID 4L9A) is covalently labeled by 
two serine hydrolase probes, whereas Smu. 1393c S99A, antigen 85-A (PDB ID 1SFR), and phosphoribosyl 
isomerase (PDB ID 2Y85) are not covalently labeled. For each serine hydrolase probe we include a parallel 
coomassie stained SDS-PAGE gel showing the presence of protein candidates. (b) We show that candidates 
Smu. 1393c (blue triangle), antigen 85-A (orange), and phosphoribosyl isomerase (green) interact with 
the serine hydrolase probe as predicted and confirm the diminished binding of Smu. 1393c S99A (inverted 
blue triangle). (c) We show the activity of Smu. 1393c against p-nitrophenyl acetate uninhibited (black 
triangles) and inhibited with demeton-S-methyl (DSM) (red circles). (d,e) We show that Smu. 1393c 
catalyzes the hydrolysis of organophosphates omethoate (d) and paraoxon (e) with the initial velocity plot 
fitted to Michaelis-Menten equation. (f) We show that Smu. 1393c protects AChE activity with (i) AChE 
uninhibited positive control (black), (ii) protected AChE activity from demeton-S-methyl (blue filled) and 
diisopropylfluorophospate (red filled), and (iii) AChE inhibited negative controls, demeton-S-methyl (blue 
outline) and diisopropylfluorophospate (red outline). All experiments were run in triplicate.
kcat (s−1) (10−3) Km (mM) kcat/Km (M−1s−1)
PNP-ac 42 ± 4 6.7 ± 1.3 6.3 ± 1.3
PNP-ac + DSM 22 ± 3 6.0 ± 1.9 3.6 ± 1.3
Paraoxon* 25 ± 0.9 (5.5 ± 1) × 10−3 (4.6 ± 0.8) × 103
Omethoate 0.52 ± 0.09 2.6 ± 1.6 0.2 ± 0.13
Table 1.  Kinetic parameters for Smu. 1393c with substrate PNP-ac, PNP-ac and inhibitor DSM, paraoxon 
and omethoate. *Smu. 1393c expressed with zinc.
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All measurements are expressed as relative activity to uninhibited AChE. We observe that Smu. 1393c protects 
AChE from full inhibition, preserving 84.4 ± 4.1% of activity for DSM and 76 ± 10% for DFP. Additionally, we 
find no significant change between the Km of active AChE (3.05 ± 0.79 mM) and inhibited AChE (4.43 ± 0.63 mM 
for DSM and 3.2 ± 1.3 mM for DFP). These results indicate that Smu. 1393c may act as an OP bioscavenger to 
protect AChE from inhibition.
Smu. 1393c activity against OPs. To investigate whether Smu. 1393c functions catalytically against OPs, 
we first use DSM as a V-agent analog. We find that Smu. 1393c shows unanticipated catalytic activity against DSM 
but are unable to complete the kinetic assays as the concentrations required to reach kinetic saturation exceed our 
supply. Additionally, to fully test the hydrolysis of the G-agent analog DFP requires an experimental setup unsup-
ported in our laboratory. These reasons necessitate our change from DFP and DSM to paraoxon and omethoate 
as G- and V-agent analogs respectively (Supplementary Fig. 2). After a series of kinetic assays we find that Smu. 
1393c catalyzes the hydrolysis of omethoate with a kcat/Km of (2.0 ± 1.3) × 10−1 M−1s−1 (Fig. 3d, Table 1). When 
we test paraoxon hydrolysis the activity level is below the sensitivity of our instruments. Intriguingly, when we 
express Smu. 1393c with zinc and then test activity we see hydrolysis of paraoxon with a kcat/Km of (4.6 ± 0.8) × 103 
M−1s−1 (Fig. 3e, Table 1) and a loss of detectable omethoate activity. These findings suggest two different catalytic 
mechanisms. Interestingly, when we perform the same tests with Smu. 1393c S99A mutant we find no activity for 
either omethoate or paraoxon, suggesting that Ser99 is crucial in both mechanisms.
Discussion
OP poisoning is a worldwide problem with an estimated 3,000,000 people exposed yearly with up to 200,000 
fatalities20,21. The availability of cheap and effective therapeutics becomes a necessity, as developing countries 
use OP pesticides in agriculture22. Additional concern lies in exposure to the more toxic variety of OPs, namely 
OP chemical nerve agents. These chemical weapons are cheap, deadly and present a viable threat in warfare or 
terrorist attack scenarios. The current preventative measures employed by military personnel include protective 
equipment and rigorous decontamination procedures23. These measures are only effective if a priori intelligence 
of an exposure situation allows proper implementation. What is needed is a molecular therapeutic designed to 
prevent AChE inhibition such as a stoichiometric bioscavenger, to competitively bind OPs, or a catalytic bioscav-
enger, to degrade OP chemicals. BChE, the current stoichiometric bioscavenger candidate, has a high molecular 
weight and high cost of production10, both of which limit its effectiveness.
Here we present three low molecular weight, producible bioscavenger candidates, antigen 85-A and phos-
phoribosyl isomerase from Mycobacterium tuberculosis and Smu. 1393c from Streptococcus mutans. Analysis of 
the structures reveals both antigen 85-A and Smu. 1393c have a core structure of an α /β hydrolase, and fall within 
the same fold class as AChE and BChE, but have less than five percent identity with either AChE or BChE18. 
Phosphoribosyl isomerase is unique among the three candidates with a core structure of a (β /α )8-barrel scaffold24. 
These candidates are predicted to form non-covalent interactions with OPs and are experimentally verified using 
serine hydrolase probes with equilibrium binding constants between 4 and 120 μ M.
We establish that Smu. 1393c has the potential to protect AChE from inhibition. To be considered an OP 
bioscavenger there remains further investigation to determine the immunological effects from introducing 
such a foreign protein into the immune system. Additionally we show that Smu. 1393c has activity against OP 
omethoate (kcat/Km of (2.0 ± 1.3) × 10−1 M−1s−1) in the absence of zinc but is active against paraoxon (kcat/Km of 
(4.6 ± 0.8) × 103 M−1s−1) when zinc is present. Examining the crystal structure of Smu. 1393c, we find a prepon-
derance of histidine residues in the same cleft where the active serine (Ser99) is located that we suspect may aid in 
metal coordination (Supplementary Fig. 7). This hypothesis will be the subject of further investigations to under-
stand the exact mechanism behind Smu. 1393c’s hydrolysis activity. The level of activity that Smu. 1393c possesses 
falls far below that of metal-binding proteins, such as human paraoxonase-1 or organophosphate hydrolase. For 
Smu. 1393c to be a competitive organophosphate will require redesign of the hydrolysis mechanism.
By identifying these bioscavenger candidates we demonstrate our computational workflow (Supplementary Fig. 8) 
which combines two successful algorithms; (i) Erebus15, a structural database search algorithm to identify mol-
ecules with substructures matching the query template; and (ii) MedusaDock16, a small molecule docking algo-
rithm to predict the probability of interaction (see Supplementary text). We believe that with further development 
and automation, this workflow can be extended into applications benefitting both the pharmaceutical industry 
and the biotech community. Specifically, by aiding in drug adverse side-effect studies, molecular therapeutics, 
epitope vaccine design, drug repurposing, and protein sensor design.
Materials and Methods
Search for Novel Scaffolds. To effectively search the PDB database (www.rcsb.com), currently containing 
over 100,000 structures (December 2014), we select all proteins with less than 350 residues and less than four sub-
units. We search this subset using the rigid substructure search algorithm Erebus15 by submitting a target scaffold 
defined by a group of atoms with known coordinates. The active site target scaffold we use is constructed using 
the hydroxyl oxygen from Ser203, the carboxylic oxygen from Glu334, the tele nitrogen from His447, all from the 
catalytic triad as oriented in the crystal structure of AChE (PDB ID 1F8U). We also include the indolic nitrogen 
from Trp86 to describe the binding pocket diameter. We use the default settings and set the RMSD cutoff at five 
angstroms. The final input scaffold consists of atoms with associated Cartesian coordinates formatted in the PDB 
style. Our starting query is below:
ATOM 1543 OG SER A 203 116.605 106.967-138.509 1.00 53.76 O
ATOM 3355 ND1 HIS A 447 116.432 102.538-135.187 1.00 56.88 N
ATOM 2485 OE1 GLU A 334 114.554 100.680-134.867 1.00 62.46 O
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ATOM 634 NE1 TRP A 86 125.948 105.322-133.913 1.00 37.58 N
Additionally, the computational cost of Erebus is minimal, taking a few minutes to hours, depending on the 
number of atoms in the search query, to search the entire structural database. For our query, the structural data-
base was searched in ~1.5 hours.
Docking Simulations. We perform redocking of VX with BChE (PDB ID 2XQF) (Fig. 1c) as a control to 
benchmark the docking method and to obtain the reference distribution of docking scores for the native complex 
as well as with AChE (PDB ID 1F8U). The input files for MedusaDock25 consist of (1) the target protein in PDB 
format, (2) the ligand of interest in a Mol2 format, and (3) the center for the search sphere marked by a small 
molecule or atom in the Mol2 format. To screen the 21 protein candidates we dock each candidate 100 times, 
each docking attempt is independent and includes ligand conformational sampling and simulated annealing. We 
select the top three candidates and dock them 1,000 times to extract a predicted binding energy distribution to 
compare to the reference distributions, where the frequency histogram plotted is the number of docked poses that 
fall within that bin. The computational cost of one MedusaDock calculation is on average between 4–6 minutes. 
To achieve results in a timely manner we distributed the 1,000 docking experiments over the killdevil computer 
cluster at the University of North Carolina Chapel Hill.
Protein Expression and Purification. We optimize the candidate protein gene sequences for expres-
sion in E. coli with an added poly-his tag and TEV protease site at the N-termini and clone the genes into the 
pET14B vector for expression in the E. coli strain BL21 (DE3) pLysS. We grow the cells in both standard LB (Smu. 
1393c and phosphoribosyl isomerase) and super broth (antigen 85-A). For the case of the catalytically active 
Smu. 1393c, we grow the cells in standard LB with 0.5 mM ZnCl2. In all cases, we induce expression with 1 mM 
Isopropyl β -D-1-thiogalactopyranoside (IPTG) at 25 °C overnight for phosphoribosyl isomerase and Smu. 1393c, 
and 72 hours at 18 °C for antigen 85-A. The collected cells are stored at − 80 °C until use.
To purify we defrost the cell pellets on ice and resuspend in buffer A (50 mM phosphate pH 7.4, 500 mM NaCl, 
40 mM imidazole, 5 mM β ME, and 0.1 μ M Pepstatin A). We use sonication to lyse the cells and centrifuge them 
in a Beckman J-20 rotor at 15,000 g for 2 hours. We collect and filter the supernatant through a 0.22 μ m filter 
before loading on a 5 mL HisTrap FF column from GE. We elute the protein with a gradient to buffer B (50 mM 
phosphate pH 7.4, 150 mM NaCl, 1 M imidazole). We then dialyze the proteins against 20 mM Tris pH 7.4 and 
elute from a HiTrap Q FF column from GE. We perform all column runs using a BioRad BioLogic low-pressure 
chromatography machine.
Fluorophosphonate labeling and fluorescence polarization. We label each protein with both 
ActiveX Tamra fluorophosphonate serine hydrolase probe (TFP-probe) for fluorescent gel scanning, and 
ActiveX Desthiobiotin fluorophosphonate serine hydrolase probe (DFP-probe) to show binding via western 
blot. Both probes are purchased from Thermo Scientific. We follow the provided protocol with minor modifi-
cations. We dilute the probe into a 2 μ M stock solution and calculate the necessary ratio of 1:30 to be 167 nM of 
probe to 5 μ M protein in a 20 μ L reaction. We incubate each protein sample with the probes for 15–30 minutes 
at room temperature. The reaction is quenched by adding 5 μ L of SDS-PAGE loading dye (200 mM Tris pH 6.8, 
10 mM β ME 10% SNS, 30% glycerol and bromophenol blue) and boiled for 5 minutes. We analyze each sample 
by fluorescent gel scanning or western blot. As a negative control we include for each protein a sample with no 
probe.
We perform fluorescence polarization using the TFP-probe as substrate. We dilute the TFP-probe to a 200 nM 
concentration and titrate the given protein measuring the change in polarization until saturation. We fit the 
obtained data first to a one site-specific binding model, = ∗
+
Y Bmax X
K X( )d
, and then to a one site-specific binding model 
with Hill slope, = ∗
+
Y Bmax X
K X( )
h
d
h h
. There is no substantial difference between the fits for phosphoribosyl isomerase, 
antigen 85-A, and Smu. 1393c S99A. We find that the one site-specific binding model with Hill coefficient pro-
duces a better fit for Smu. 1393c (Hill coefficient = 2.0 ± 0.06).
AChE protection assays. We purchase lyophilized Electrophorus electricus AChE, demeton-S-methyl, 
and diisopropylfluorophosphate from Sigma Aldrich. We run a modified protocol from Cherny et al.19, where 
standard Ellman assays recover kinetic parameters26 and determine the ability of Smu. 1393c to protect AChE 
from the effects of OP simulants. We incubate equal amounts of Smu. 1393c and OP simulant (final concen-
tration 500 nM) at 20 °C for 30 minutes. We add AChE to each sample and incubate at 20 °C for 60 minutes. 
As a detectable marker we add 500 μ M of the Ellman reagent 5,5-dithio-bis-(2-nitrobenzoic acid) (DTNB) 
to the samples. We vary the amount of acetylthiolcholine (0–20 mM) and bring each sample to a volume of 
50 μ L using buffer (200 mM NaCl, 20 mM TRIS at pH 7.4). Each assay is performed in triplicate. We plot the 
kinetic parameters, obtained using SpectraMax M3 plate reader, and fit them to the Michaelis-Menton kinetic 
equation.
Smu. 1393c catalytic assays. We verify the catalytic activity of Smu. 1393c by observing the absorbance 
of the p-nitrophenyl group detectable at 405 nm marking the hydrolysis of p-nitrophenyl acetate (PNP-ac). We 
also assay the inhibition potential of demeton-S-methyl. We plot and fit the kinetic parameters to the Michaelis- 
Menton kinetic equation and calculate the inhibition constant by =+
+
−
( )Vmax
I Vmax
1
I
I
Ki
[ ]
. We determine the activity 
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of Smu. 1393c against both paraoxon and omethoate using absorbance. For paraoxon we detect the 
p-nitrophenyl group at 405 nm. To monitor the omethoate hydrolysis we use an Ellman assay26. We perform 
each assay in triplicate investigating paraoxon concentrations between 0–300 μ M and omethoate concentra-
tions between 0–18 mM. Each assay is brought to 1000 μ L with 50 mM bis-tris-propane pH 7.4. We initiate the 
catalytic reaction by adding Smu. 1393c for a final concentration of 72 nM for paraoxon, and 5 μ M for 
omethoate. Additionally, we perform negative controls without Smu. 1393c. We analyze the data by subtracting 
the negative controls from the calculated initial velocities. We plot and fit the kinetic parameters to the 
Michaelis-Menton kinetic equation.
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